The Rot at the FDA: A Pattern of Politics Over Science

The Food and Drug Administration has long been seen as a bulwark against corruption and special interests in American healthcare, but lately it’s become clear that this institution is riddled with the same problems it was meant to prevent.

Dr. Tracy Beth Hoeg, an agency official who scrutinized the safety of antidepressants, COVID-19 vaccines, and other widely used therapies, has stepped down from her role leading the agency’s drug program. Her departure is a symptom of a larger malaise afflicting the FDA.

The revolving door at the FDA has long been a concern for those who value scientific integrity over politics. However, the recent exodus of top officials suggests that something more insidious is at play. Dr. Marty Makary, the former commissioner, resigned earlier in the week amidst complaints from President Donald Trump’s allies – anti-abortion groups and vaping lobbyists frustrated with the agency’s direction.

The FDA’s current turmoil has its roots in a series of questionable decisions made under the previous administration. The appointment of Hoeg to lead the drug program was seen as particularly egregious because she had no prior government or management experience, yet rose through the ranks courtesy of Makary and Health Secretary Robert F. Kennedy Jr.

Hoeg’s rapid ascent was mirrored by her involvement in some of the most contentious issues facing the agency – COVID-19 vaccines, antidepressants, and RSV drugs for children. Her investigations reflected a longstanding concern with government measures during the pandemic, including masking, school closures, and vaccine mandates. While these opinions may have been expressed in good faith, they also underscore the blurred lines between science and ideology that now define the FDA.

The agency’s failure to maintain scientific integrity is compounded by its willingness to indulge contrarian views. Hoeg was involved in an initial analysis of vaccine injuries that linked COVID-19 shots to 10 reported deaths in children – without providing supporting evidence, raising serious questions about the agency’s commitment to fact-based decision-making.

The FDA’s handling of antidepressant drugs also warrants scrutiny. Hoeg reviewed a formal petition to add bold new warnings about unproven pregnancy risks, including fetal abnormalities that could lead to autism and other disorders. Her attempts to hire the author of this petition as a senior adviser at the agency have sparked concerns among some staff members.

The FDA’s current leadership shake-up is far from over. The departure of Dr. Vinay Prasad, the agency’s vaccine and biotech chief, last month followed intense criticism from drugmakers, patients, and investors. Meanwhile, Karim Mikhail has taken over as acting director of the vaccines center – a decision that has raised eyebrows given his background as a pharmaceutical executive.

As the FDA struggles to regain its footing, it is clear that the agency’s commitment to scientific integrity must be reasserted. The rot at the FDA will only continue to spread if policymakers and regulators fail to take action.